ATE461996T1 - Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung - Google Patents

Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung

Info

Publication number
ATE461996T1
ATE461996T1 AT00954883T AT00954883T ATE461996T1 AT E461996 T1 ATE461996 T1 AT E461996T1 AT 00954883 T AT00954883 T AT 00954883T AT 00954883 T AT00954883 T AT 00954883T AT E461996 T1 ATE461996 T1 AT E461996T1
Authority
AT
Austria
Prior art keywords
compositions
alzheimer
disease
prevention
compounds
Prior art date
Application number
AT00954883T
Other languages
English (en)
Inventor
Beka Solomon
Dan Frenkel
Eilat Hanan
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/473,653 external-priority patent/US6703015B1/en
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE461996T1 publication Critical patent/ATE461996T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT00954883T 1999-09-03 2000-08-31 Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung ATE461996T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15241799P 1999-09-03 1999-09-03
US09/473,653 US6703015B1 (en) 1999-09-03 1999-12-29 Filamentous bacteriophage displaying an β-amyloid epitope
US62997100A 2000-07-31 2000-07-31
PCT/IL2000/000518 WO2001018169A2 (en) 1999-09-03 2000-08-31 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases

Publications (1)

Publication Number Publication Date
ATE461996T1 true ATE461996T1 (de) 2010-04-15

Family

ID=27387248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00954883T ATE461996T1 (de) 1999-09-03 2000-08-31 Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung

Country Status (11)

Country Link
US (4) US6919075B1 (de)
EP (1) EP1180938B1 (de)
JP (1) JP2003509020A (de)
AT (1) ATE461996T1 (de)
AU (1) AU784568B2 (de)
CA (1) CA2349434A1 (de)
DE (1) DE60044057D1 (de)
ES (1) ES2344189T3 (de)
HK (1) HK1044564B (de)
IL (1) IL142948A0 (de)
WO (1) WO2001018169A2 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
JP2003516929A (ja) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド アミロイド形成性疾患の予防および治療
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
EP2165714B1 (de) 2001-04-30 2013-10-23 Eli Lilly And Company Humanisierte Antikörper die das Beta-Amyloid Peptid erkennen
EP1385544B1 (de) 2001-04-30 2008-09-24 Eli Lilly And Company Humanisierte antikörper
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
EP1480666B1 (de) 2002-03-05 2012-06-13 Ramot at Tel-Aviv University Ltd. Immunisierende zusammensetzung und verfahren zur auslösung einer immunantwort gegen die beta-secretase-cleavage-stelle von amyloid-vorläuferprotein
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1524994B1 (de) * 2002-07-19 2011-04-27 Cytos Biotechnology AG Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20050225165A1 (en) * 2004-04-13 2005-10-13 Naik Sanjeev M Brake by-wire control system
EP2332569A3 (de) * 2004-06-25 2011-09-14 ID Biomedical Corporation of Quebec Zusammensetzungen und Verfahren zur Behandlung von neurologischen Erkrankungen
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
CN101080421A (zh) * 2004-08-11 2007-11-28 三菱化学株式会社 抗体以及其利用
JPWO2006030722A1 (ja) * 2004-09-15 2008-05-15 公立大学法人横浜市立大学 神経特異的遺伝子発現に必須なアミノ酸配列
US20060160161A1 (en) * 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1853285B1 (de) * 2005-02-01 2011-03-16 Ramot at Tel-Aviv University Ltd. Verfahren zur behandlung von entzündungen in zusammenhang mit amyloid-ablagerungen und hirnhautentzündung unter beteiligung aktivierter mikroglia
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
CA2632822C (en) * 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP1991259B1 (de) * 2006-02-15 2012-10-10 Ramot at Tel-Aviv University Ltd. Virale display-vehikel zur behandlung von multipler sklerose
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
WO2008011503A2 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2099826B1 (de) 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid-antikörper und verwendung davon
HRP20150237T1 (hr) 2007-01-18 2015-04-10 Eli Lilly And Company Pegilirani fab protiv amiloida-beta
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8470321B2 (en) 2007-11-16 2013-06-25 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
ITNA20080006A1 (it) * 2008-01-28 2009-07-29 Consiglio Nazionale Ricerche Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp
US20110182809A1 (en) * 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG171791A1 (en) * 2008-11-24 2011-07-28 Univ Ramot Method for treating parkinson' s disease using filamentous bacteriophage
EP3521309A1 (de) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
JP5905457B2 (ja) * 2010-07-02 2016-04-20 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 尿路感染症（ｕｔｉ）ワクチン
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
EP3527220A1 (de) 2010-08-12 2019-08-21 AC Immune S.A. Manipulation von impfstoffen
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
CA2813833C (en) 2010-10-26 2020-09-22 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
US8877446B2 (en) * 2011-08-26 2014-11-04 Korea Research Institute Of Bioscience And Biotechnology Method for detecting protein-protein interactions in cells
JP2012102131A (ja) * 2012-01-05 2012-05-31 Elan Pharma Internatl Ltd アミロイド形成性疾患の予防および治療
US20150344542A1 (en) * 2012-12-27 2015-12-03 Spiber Inc. Partial purification method for hydrophilic recombinant protein
WO2014103846A1 (ja) * 2012-12-27 2014-07-03 スパイバー株式会社 親水性組換えタンパク質の抽出方法
EP2970917A2 (de) 2013-03-15 2016-01-20 Altria Client Services LLC Bakteriophage und verfahren zur herstellung und verwendung
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US9968682B2 (en) 2013-04-25 2018-05-15 Spiber Inc. Polypeptide hydrogel and method for producing same
WO2014175178A1 (ja) 2013-04-25 2014-10-30 スパイバー株式会社 ポリペプチド多孔質体及びその製造方法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016123425A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Endolysin from bacteriophage against geobacillus and methods of using
WO2016123427A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Bacteriophage and methods of using
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
EP4233901A3 (de) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmazeutische zusammensetzungen mit anti-beta-amyloid-antikörpern
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
CA2231409C (en) * 1995-09-14 2003-02-11 The Regents Of The University Of California Antibodies specific for native prpsc
GB9626675D0 (en) * 1996-12-23 1997-02-12 Procter & Gamble Hair coloring compositions
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
US20020140675A1 (en) * 1999-01-25 2002-10-03 Ali Ammar Al System and method for altering a display mode based on a gravity-responsive sensor
AU6722300A (en) * 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
US6597384B1 (en) * 1999-12-22 2003-07-22 Intel Corporation Automatic reorienting of screen orientation using touch sensitive system
US6621508B1 (en) * 2000-01-18 2003-09-16 Seiko Epson Corporation Information processing system
US20030148404A1 (en) * 2000-07-27 2003-08-07 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders

Also Published As

Publication number Publication date
EP1180938B1 (de) 2010-03-24
WO2001018169A2 (en) 2001-03-15
EP1180938A2 (de) 2002-02-27
CA2349434A1 (en) 2001-03-15
ES2344189T3 (es) 2010-08-20
EP1180938A4 (de) 2005-03-16
US6919075B1 (en) 2005-07-19
IL142948A0 (en) 2002-04-21
WO2001018169A3 (en) 2001-11-22
US20050089510A1 (en) 2005-04-28
US20030077252A1 (en) 2003-04-24
AU784568B2 (en) 2006-05-04
AU6723200A (en) 2001-04-10
HK1044564A1 (en) 2002-10-25
DE60044057D1 (de) 2010-05-06
US20050152878A1 (en) 2005-07-14
HK1044564B (en) 2010-05-28
JP2003509020A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
ATE461996T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
WO2002074243A3 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
RU2432364C2 (ru) ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
WO2003076455A3 (en) Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
MX2007000998A (es) Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
CY1118381T1 (el) Ανθρωποποιημενα αντισωματα που απομακρυνουν το αμυλοειδες βητα πεπτιδιο
ATE425987T1 (de) Gereinigtes antigen fur die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
DE69723434D1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
NO983999D0 (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
EP0671927A4 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialviru.
SG173214A1 (en) Immunological methods and compositions for the treatment of alzhemier's disease
ATE516819T1 (de) Verfahren zur behandlung von b-zell-bedingtem krebs
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
EP0954529A4 (de) Porphyromonas gingivalis Antigen zur Diagnose und Behandlung von Periodontitis
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
Wardemann et al. From human antibody structure and function towards the design of a novel Plasmodium falciparum circumsporozoite protein malaria vaccine
ATE335821T1 (de) Verfahren und zusammensetzungen zur diagnose von rochalimaea henselae und rochalimaea quintana infektion
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
ATE440616T1 (de) Verfahren zur steigerung der antigenimmunogenität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties